Abhisek Banerjee

This inventor holds 11 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Glenmark Pharmaceuticals S.a.. Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Abhisek Banerjee. Retrieved from https://idiyas.com/inventor/abhisek-banerjee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 90.9

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

West Bengal, IN (2015 - 2019)
Howrah, IN (2013 - 2021)

Company Filing History:

10 out of 3,749

Bristol-Myers Squibb Compnay

patents

1 out of 65

Glenmark Pharmaceuticals S.a.

patents

Years Active: 2013-2021

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11008306 - Quinazolines as potassium ion channel inhibitors (2021-05-18),

2. 10676460 - Quinazolines as potassium ion channel inhibitors (2020-06-09),

3. 10227340 - Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors (2019-03-12),

4. 10214511 - Quinazolines as potassium ion channel inhibitors (2019-02-26),

5. 9862715 - Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors (2018-01-09),

6. 9458114 - Quinazolines as potassium ion channel inhibitors (2016-10-04),

7. 9242976 - Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors (2016-01-26),

8. 9242975 - Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors (2016-01-26),

9. 9006257 - Bicyclic compounds as mPGES-1 inhibitors (2015-04-14),

10. 8987311 - Triazolyl-substituted pyridyl compounds useful as kinase inhibitors (2015-03-24),

11. 8575184 - Quinazolines as potassium ion channel inhibitors (2013-11-05),

Title: Abhisek Banerjee: Innovator in Potassium Ion Channel Inhibitors

Introduction

Abhisek Banerjee is a notable inventor based in Howrah, India. He has made significant contributions to the field of pharmacology, particularly in the development of potassium ion channel inhibitors. With a total of 11 patents to his name, Banerjee's work has the potential to impact the treatment of various cardiac and ion channel-related disorders.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Quinazolines as potassium ion channel inhibitors." This patent describes a compound of formula I, wherein A, X, Y, Z, R, and R are specified. The compounds developed by Banerjee are particularly useful as inhibitors of potassium channel function and are aimed at the treatment and prevention of arrhythmia and other disorders mediated by ion channel function.

Career Highlights

Throughout his career, Abhisek Banerjee has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Bristol-Myers Squibb Company and Glenmark Pharmaceuticals S.A. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Banerjee has collaborated with several professionals in his field, including Satheesh Kesavan Nair and Venkatram Reddy Paidi. These collaborations have likely enhanced his research and development efforts, leading to his successful patent applications.

Conclusion

Abhisek Banerjee stands out as an influential inventor in the realm of potassium ion channel inhibitors. His innovative work and numerous patents reflect his commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.